Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qlife Holding ABOSTO:QLIFE +1.47%40 3-Year EBITDA Growth Rate is 88.70% as of Jun. 2026, which is at its 10-year median of 88.70. GuruFocus rates OSTO:QLIFE with a GF Score™ of 40/100 and a GF Value™ of kr2.05 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Qlife Holding AB ranks better than 97.68% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 88.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 81.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Qlife Holding AB was 96.40% per year. The lowest was 6.80% per year. And the median was 88.70% per year.
Qlife Holding AB (OSTO:QLIFE) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Qlife Holding AB 3-Year EBITDA Growth Rate Related Terms
OSTO:QLIFE vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Qlife Holding AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qlife Holding AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qlife Holding AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Qlife Holding AB's 3-Year EBITDA Growth Rate falls into.
Qlife Holding AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 88.70% mean?
Qlife Holding AB (OSTO:QLIFE) has a 3-Year EBITDA Growth Rate of 88.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Qlife Holding AB and its competitors. This is near median its historical median of 88.70. Over the past decade, Qlife Holding AB's 3-Year EBITDA Growth Rate has ranged from 6.80 to 96.40. According to the industry distribution chart, Qlife Holding AB ranks #16 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 2.3%.
Is Qlife Holding AB's 3-Year EBITDA Growth Rate too high?
Qlife Holding AB's current 3-Year EBITDA Growth Rate of 88.70% is near median its 10-year median of 88.70. Over the past 10 years, this metric has ranged from a low of 6.80 to a high of 96.40. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Qlife Holding AB's value of 88.70% is 995.1% above this industry median. Based on the distribution chart, Qlife Holding AB ranks #16 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Qlife Holding AB has a GF Score™ of 40/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qlife Holding AB ranks #16 out of 690 companies for 3-Year EBITDA Growth Rate. This places Qlife Holding AB in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. Qlife Holding AB's value of 88.70% is 995.1% above this benchmark. Historically, Qlife Holding AB's own 3-Year EBITDA Growth Rate has ranged from 6.80 to 96.40 over the past decade. While the company's 10-year median is 88.70 vs. the industry median of 8.10, Qlife Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qlife Holding AB's current 3-Year EBITDA Growth Rate of 88.70% is 995.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Qlife Holding AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qlife Holding AB's current 3-Year EBITDA Growth Rate is 88.70%, which is near median its own 10-year median of 88.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2.05, compared to a current price of kr1.80 — trading 12.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 88.70%, which is near median its 10-year median of 88.70 and 995.1% above the Medical Devices & Instruments industry median of 8.10. Qlife Holding AB's overall GF Score™ is 40/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current 3-Year EBITDA Growth Rate is 88.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Qlife Holding AB stock appears to be undervalued.
The current stock price of kr1.80 is trading 12.3% below its estimated GF Value™ of kr2.05.
GuruFocus considers Qlife Holding AB to be Modestly Undervalued.
Key valuation signals for OSTO:QLIFE:
3-Year EBITDA Growth Rate: 88.70% (near median its 10-year median of 88.70)
GF Value™: kr2.05 vs. price of kr1.80 (12.3% below fair value)
Industry Position: 995.1% above the Medical Devices & Instruments median (#16 of 690)
No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
40GF Score
Get the complete analysis for OSTO:QLIFE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:QLIFE has been successfully added to your 
